Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Halneuron in Chemotherapy-induced neuropathic pain. The expected timing is based on the latest available company guidance and may change.
05/14/26:- HALT-CINP enrolled 164 patients; Ph2b top-line results remain expected Fall 2026. 05/18/26:- Ph2b 12-week extension began. Topline results still expected Fall 2026. Ph3 start projected H1 2027. 07/20/26:- HAL-CINP (NCT06848348) enrolled 200; unblinded review showed placebo separation. Topline data still expected Fall 2026. 08/13/26:- Halneuron Phase 2b CINP study enrolled 217 patients. Topline results remain expected Fall 2026. A 12-week extension study began.
Verification
Confirm timing and program details against the company announcement or filing.